JP7828286B2 - 抗ｍｕｃ１－ｓｅａ抗体 - Google Patents

抗ｍｕｃ１－ｓｅａ抗体

Info

Publication number
JP7828286B2
JP7828286B2 JP2022555992A JP2022555992A JP7828286B2 JP 7828286 B2 JP7828286 B2 JP 7828286B2 JP 2022555992 A JP2022555992 A JP 2022555992A JP 2022555992 A JP2022555992 A JP 2022555992A JP 7828286 B2 JP7828286 B2 JP 7828286B2
Authority
JP
Japan
Prior art keywords
antibody
muc1
seq
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022555992A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021186427A5 (https=
JP2023517754A (ja
JP2023517754A5 (https=
Inventor
ルビンスタイン，ダニエル
レシュナー，ダニエル
Original Assignee
バイオモディファイング・エルエルシー
ラモット アット テル アビブ ユニバーシティ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオモディファイング・エルエルシー, ラモット アット テル アビブ ユニバーシティ， リミテッド filed Critical バイオモディファイング・エルエルシー
Publication of JP2023517754A publication Critical patent/JP2023517754A/ja
Publication of JPWO2021186427A5 publication Critical patent/JPWO2021186427A5/ja
Publication of JP2023517754A5 publication Critical patent/JP2023517754A5/ja
Application granted granted Critical
Publication of JP7828286B2 publication Critical patent/JP7828286B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
JP2022555992A 2020-03-18 2021-03-11 抗ｍｕｃ１－ｓｅａ抗体 Active JP7828286B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18
US62/991,077 2020-03-18
PCT/IL2021/050269 WO2021186427A1 (en) 2020-03-18 2021-03-11 Anti- muc1-sea antibodies

Publications (4)

Publication Number Publication Date
JP2023517754A JP2023517754A (ja) 2023-04-26
JPWO2021186427A5 JPWO2021186427A5 (https=) 2024-03-18
JP2023517754A5 JP2023517754A5 (https=) 2024-03-18
JP7828286B2 true JP7828286B2 (ja) 2026-03-11

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555992A Active JP7828286B2 (ja) 2020-03-18 2021-03-11 抗ｍｕｃ１－ｓｅａ抗体

Country Status (20)

Country Link
US (1) US20230085269A1 (https=)
EP (1) EP4087879A1 (https=)
JP (1) JP7828286B2 (https=)
KR (1) KR20220161267A (https=)
CN (1) CN115667312A (https=)
AU (1) AU2021239078A1 (https=)
BR (1) BR112022018629A2 (https=)
CA (1) CA3171531A1 (https=)
CL (1) CL2022002520A1 (https=)
CO (1) CO2022014726A2 (https=)
CR (1) CR20220523A (https=)
CU (1) CU20220055A7 (https=)
DO (1) DOP2022000193A (https=)
EC (1) ECSP22080687A (https=)
IL (1) IL296572A (https=)
MX (1) MX2022011553A (https=)
PE (1) PE20230602A1 (https=)
PH (1) PH12022552445A1 (https=)
WO (1) WO2021186427A1 (https=)
ZA (1) ZA202211303B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
EP4676976A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 antibodies and methods of use
AU2024318998A1 (en) 2023-07-31 2026-01-22 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate
WO2026078593A1 (en) 2024-10-08 2026-04-16 Sun Pharma Advanced Research Company Limited Sting agonists and antibody drug conjugates thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528623A (ja) 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
WO2018174544A2 (ko) 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
WO2019094626A1 (en) 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
ES2823351T3 (es) * 2013-12-19 2021-05-06 Arocell Ab Anticuerpos anti-TK1 monoclonales
IL269488B2 (en) * 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528623A (ja) 2005-01-28 2008-07-31 ラモット アット テル アビブ ユニバーシティ， リミテッド 抗ＭＵＣ１のα／β抗体
WO2018174544A2 (ko) 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
WO2019094626A1 (en) 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research，2012年，72(13)，pp.3324-3336

Also Published As

Publication number Publication date
CR20220523A (es) 2023-01-23
CA3171531A1 (en) 2021-09-23
CU20220055A7 (es) 2023-06-13
WO2021186427A1 (en) 2021-09-23
KR20220161267A (ko) 2022-12-06
US20230085269A1 (en) 2023-03-16
AU2021239078A1 (en) 2022-08-11
MX2022011553A (es) 2023-01-04
DOP2022000193A (es) 2023-03-23
CL2022002520A1 (es) 2023-03-10
JP2023517754A (ja) 2023-04-26
BR112022018629A2 (pt) 2023-03-07
CO2022014726A2 (es) 2023-02-16
CN115667312A (zh) 2023-01-31
PH12022552445A1 (en) 2023-11-20
EP4087879A1 (en) 2022-11-16
IL296572A (en) 2022-11-01
PE20230602A1 (es) 2023-04-10
ECSP22080687A (es) 2022-12-30
ZA202211303B (en) 2025-08-27

Similar Documents

Publication Publication Date Title
CN113166246B (zh) 一种抗体及其用途
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
JP7842703B2 (ja) 抗Ｃｌａｕｄｉｎ１８．２抗体およびその使用
JP7828286B2 (ja) 抗ｍｕｃ１－ｓｅａ抗体
JP2021120382A (ja) 部位特異的抗体コンジュゲーション方法および組成物
EP2014302A1 (en) An antibody specific for the Tn antigen for the treatment of cancer
CN101679526A (zh) 介导癌细胞细胞毒性的人源化和嵌合抗trop-2抗体
US20230331867A1 (en) Nectin-4 antibodies and uses thereof
CN105017420A (zh) 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
CN107001452A (zh) 用于治疗癌症的抗ck8抗体
KR20090130335A (ko) 암 세포 세포독성을 매개하는 인간화 및 키메라 항-ｃｄ５９ 항체
KR20230156021A (ko) Ror1 결합 단백질 및 이의 용도
EP4070816A1 (en) Anti-gdf15 antibody
EP4079758A1 (en) Semg2 antibody and use thereof
EA049289B1 (ru) Антитела к sea-muc1
OA20958A (en) Anti- MUC1-sea antibodies
WO2024012395A1 (en) Anti-mesothelin antibodies
WO2023190465A1 (ja) 抗ヒトｓｅｍａ７ａ抗体
WO2023175117A1 (en) Antibodies against lypd3
HK40081009A (en) Anti-gdf15 antibody
IL285313A (en) Antibodies for cancer treatment
HK40048164B (zh) 一种抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260227

R150 Certificate of patent or registration of utility model

Ref document number: 7828286

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150